



Published in final edited form as:

Nat Genet. 2019 April ; 51(4): 600–605. doi:10.1038/s41588-019-0350-x.

Causal relationships between gut microbiome, short-chain fatty acids and metabolic diseases

Serena Sanna^{1,¶}, Natalie R. van Zuydam^{2,3,¶}, Anubha Mahajan^{2,3,¶}, Alexander Kurilshikov¹, Arnau Vich Vila^{1,4}, Urmo Vösa¹, Zlatan Mujagic⁵, Ad A. M. Masclee⁵, Daisy M.A.E. Jonkers⁵, Marije Oosting⁶, Leo A.B. Joosten⁶, Mihai G. Netea⁶, Lude Franke¹, Alexandra Zhernakova¹, Jingyuan Fu^{1,7}, Cisca Wijmenga^{1,8,§}, and Mark I. McCarthy^{2,3,9,§}

¹University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, the Netherlands ²Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK ³Oxford Centre for Diabetes Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford, UK ⁴University of Groningen, University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, the Netherlands ⁵Maastricht University Medical Center, Division Gastroenterology-Hepatology, NUTRIM School for Nutrition, and Translational Research in Metabolism, Maastricht, the Netherlands ⁶Department of Internal Medicine, Radboud Institute of Molecular Life Sciences (RIMLS) and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands ⁷University of Groningen, University Medical Center Groningen, Department of Pediatrics, Groningen, Groningen, the Netherlands ⁸K.G. Jebsen Coeliac Disease Research Centre, Department of Immunology, University of Oslo, Oslo, Norway ⁹Oxford NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK

Abstract

Correspondence should be addressed to S.S. (s.sanna@umcg.nl), C.W. (c.wijmenga@umcg.nl) or M.M. (mark.mccarthy@drl.ox.ac.uk).

Author Contributions

S.S. performed statistical analyses in LifeLines and 500FG cohorts; N.vZ. and A.M. performed statistical analyses in UK Biobank and DIAGRAM studies; A.K. and A.V.V. processed raw microbiome data in Lifelines-DEEP and 500FG; U.V. and L.F. downloaded and harmonized the summary statistics from GIANT, MAGIC and DIAGRAM consortia; L.F., and C.W. provided LifeLines-DEEP data; Z.M., A.A.M.M., D.M.A.E.J. provided critical input to manuscript revisions; M.O., L.J. and M.G.N. provided 500FG data; S.S., N.vZ. and M.M. wrote the manuscript, with critical input from J.F., A.Z. and C.W.; S.S., N.vZ., A.M., C.W. and M.M. designed the study.

All authors read, revised and approved the manuscript.

[¶]These authors contributed equally to this work.

[§]These authors jointly supervised this work.

Competing Interests statement

M.M. serves on advisory panels for Pfizer, NovoNordisk, Zoe Global; has received honoraria from Pfizer, NovoNordisk and Eli Lilly; has stock options in Zoe Global; has received research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier, Takeda. All other authors declare no competing financial interests.

Reporting Summary

Further information on research design is available in the Life Sciences Reporting Summary linked to this article.

Data availability

The LifeLines-DEEP metagenomics sequencing data are available at the European Genome-phenome Archive (EGA), with access code EGAS00001001704. Genotype and phenotype data can be requested from the Lifelines Biobank <https://www.lifelines.nl/researcher/biobank-lifelines/application-process>.

Summary statistics for metabolic traits were downloaded from MAGIC, GIANT and DIAGRAM websites (see URLs).

Microbiome-wide association studies on large population cohorts have highlighted associations between the gut microbiome and complex traits, including type 2 diabetes (T2D) and obesity¹. However, the causal relationships remain largely unresolved. We leveraged information from 952 normo-glycemic individuals for whom genome-wide genotyping, gut metagenomic sequence and fecal short chain fatty acid (SCFA) levels were available², and combined these with genome-wide association summary statistics for 17 metabolic and anthropometric traits. Using bidirectional Mendelian Randomization (MR) analyses to assess causality³, we found that host genetic-driven increase in gut production of the SCFA butyrate is associated with improved insulin response following an oral glucose test ($P = 9.8 \times 10^{-5}$), while abnormalities in production or absorption of another SCFA, propionate, are causally related to increased risk of T2D ($P = 0.004$). These data provide evidence of a causal effect of the gut microbiome on metabolic traits, and support the use of MR as a route to elucidate causal relationships from microbiome-wide association findings.

There is increasing evidence that the human gut microbiome plays a role in immune function and metabolic disease^{1,4,5}. Manipulation of the gut microbiome offers an alternative to pharmacological interventions provided it can be demonstrated that altering microbiota composition and/or function (e.g. through personalized nutrition) has clinical benefit. To demonstrate this, it is essential to discriminate between microbiome features that are causal for disease, from those that are a consequence of disease or its treatment, and those that show statistical correlation due to confounding or pleiotropy.

Animal studies support a causal role for the gut microbiome in the development of type 2 diabetes (T2D), insulin resistance and obesity^{6,7}, but translating these findings to humans and identifying the specific bacterial species responsible has proven challenging⁸. Cross-sectional studies have confirmed that gut microbiota composition is altered in subjects with pre-diabetes or T2D compared to controls, while fecal transplantation studies have shown that insulin sensitivity increases in obese subjects with metabolic syndrome after the transfer of gut microbiota from lean donors^{4,5,9,10}. Whilst the specific microbiome features identified as responsible for these effects have differed between studies, one consistent finding in T2D subjects is a shift in microbiome composition away from species able to produce butyrate. Butyrate and other short-chain fatty acids (SCFAs), such as acetate and propionate, are produced by gut bacterial fermentation of undigested food components. Following absorption by the colonocytes, these SCFAs are either used locally as fuel for colonic mucosal epithelial cells or they enter the portal bloodstream¹¹. While the bulk of evidence suggests that increased SCFA production benefits the host by exerting anti-obesity and anti-diabetic effects^{4,10,12-14}, some *in vitro* and *in vivo* studies have indicated that over-production or accumulation of SCFAs in the bowel may also lead to obesity due to increased energy accumulation^{15,16}. Resolution of these conflicting data requires a detailed understanding of the causal relationships between gut microbiome composition, SCFA abundance and host energy metabolism.

Using a Mendelian Randomization (MR) approach³, we set out to identify if any bacterial species or pathways, i.e. sets of species grouped according to the specific functions they play in the gut, have a causal effect on metabolic traits. We and others have recently shown that it is possible to detect variants in the host genome that influence the composition of the gut

microbiota^{2,17,18}. This allowed us to deploy a MR approach to infer causal relationships by asking whether genetic predictors of microbiome content influence metabolic traits—or the reverse. This formulation holds even though the quantitative contribution of host genetics to variation in microbiome composition may be limited¹⁹.

We assembled genome-wide genetic data, gut metagenomic-sequencing, measurements of fecal SCFAs, and clinical phenotypes for 952 normo-glycemic individuals from the LifeLines-DEEP (LL-DEEP) cohort. From consortium websites (GIANT, MAGIC and DIAGRAM, see URLs), we also gathered publically-available genome-wide association (GWA) summary statistics for 17 anthropometric and glycemic traits^{20–27} (Supplementary Table 1). We focused our analyses on 245 microbiome features (2 fecal SCFA levels, 57 unique taxa, 186 pathways) that were, in LL-DEEP, correlated (false discovery rate (FDR) < 0.1) with at least one of the measured anthropometric and metabolic traits (Methods, Supplementary Table 2 and 3).

For each of these features, we sought genetic predictors -- independent genetic variants ($r^2 > 0.1$), associated ($P < 1 \times 10^{-5}$) with the respective features – using GWAS data from LL-DEEP, reprocessed from our previous study² (Methods). The threshold $P < 1 \times 10^{-5}$ for variant inclusion was identified by maximizing the amount of genetic variance explained by the genetic predictors in 445 independent normo-glycemic individuals (the 500FG cohort)²⁸(Methods, Supplementary Figure 1), and designed to capture sets of variants likely to be enriched for association. On average, in LL-DEEP the identified genetic predictors explained 13% (range 2%–30%) of variance in their respective microbiome features. The average F-statistic, another measure of the strength of these genetic predictors, was 21.7 (range 15.3 – 25.5); an F-statistic >10 is considered sufficiently informative for MR analyses²⁹.

We used the inverse-variance weighted (IVW) test to identify causal relationships between the 245 microbiome features and the 17 traits of interest in a two-sample bidirectional MR analysis using pairs of GWAS summary statistics (one from a microbiome feature and one from a metabolic/anthropometric trait)²⁹. Based on principal component analysis (PCA) and cluster analyses conducted on the microbiome and metabolic and anthropometric traits (Methods, Supplementary Figure 2), we adopted a conservative multiple testing adjusted threshold of $P < 1.3 \times 10^{-4}$ to declare a causal relationship significant. Because the presence of horizontal pleiotropy (where a genetic predictor has independent effects on the diseases through multiple traits) could bias the MR estimates, we investigated the robustness of

URLs

MAGIC: <https://www.magicinvestigators.org/>
GIANT: http://portals.broadinstitute.org/collaboration/giant/index.php/Main_Page
DIAGRAM: <http://www.diagram-consortium.org/>
UK Biobank: <http://www.ukbiobank.ac.uk/>
Human Functional Genomics Project: <http://www.humanfunctionalgenomics.org/>
Bracken: <https://github.com/jenniferlu717/Bracken>
MetaCyc metabolic pathway database: <http://www.metacyc.org/>
PLINK: www.cog-genomics.org/plink2
Michigan imputation server: <https://imputationserver.sph.umich.edu/>
R: <https://www.r-project.org/>
LDScore: <https://github.com/bulik/ldsc>
MR-PRESSO: <https://github.com/rondolab/MR-PRESSO>

significant findings to pleiotropy by using three additional MR tests: the MR-PRESSO³⁰, the weighted median test³¹, and the MR-Egger³². We formally examined the presence of horizontal pleiotropy using the MR-PRESSO Global test³⁰ and the modified Rucker's Q' test^{33,34}. Finally, we sought to validate these causal relationships in an independent cohort (UK Biobank)³⁵ (Figure 1).

We observed a significant causal influence for one specific microbiome feature, a microbial pathway involved in 4-aminobutanoate (GABA) degradation (MetaCyc designation PWY-5022: 4-aminobutanoate degradation V) on increased insulin secretion, and specifically the ratio of the areas under the curve for insulin and glucose, $AUC_{\text{insulin}}/AUC_{\text{glucose}}$, measured during an oral glucose tolerance test (oGTT) (Figure 2a). Using nine genetic predictors (variance explained = 16%; F-statistic = 21, Supplementary Table 4), we estimated that each standard deviation (SD) increase in the abundance of PWY-5022 generated a 0.16 mU/mmol increase in $AUC_{\text{insulin}}/AUC_{\text{glucose}}$ ($P = 9.8 \times 10^{-5}$) (Supplementary Table 5, Supplementary Figure 3). This causal relationship was robust when additional MR tests were performed ($P_{\text{MR-PRESSO}} = 0.02$, $P_{\text{Weighted-Median}} = 0.02$ and $P_{\text{MR-EGGER}} = 0.02$), and there was no evidence for horizontal pleiotropy ($P_{\text{MR-PRESSOglobal}} = 0.18$ and $P_{\text{RuckerQ'(modified)}} = 0.77$) (Supplementary Figure 4). The reverse MR analysis (testing the relationship between genetic predictors of $AUC_{\text{insulin}}/AUC_{\text{glucose}}$ and PWY-5022 abundance) was not significant ($P > 0.1$, Supplementary Table 6). There was no evidence of causality with seven metabolic and anthropometric traits (body-mass index (BMI), body fat %, waist-hip ratio (WHR), visceral adipose tissue, abdominal subcutaneous adipose tissue, obesity and T2D) in a MR analyses that used UK Biobank summary statistics (Supplementary Table 7); insulin secretion phenotypes after oGTT were not available. We also found supportive evidence ($P < 0.05$) for a causal impact of this pathway on other insulin response parameters (Figure 2b). Though other types of causal relationship are possible, these data are consistent with a model whereby host genetic variation that influences gut microbiome composition so as to modulate GABA degradation activity results in improvements in the capacity of the pancreatic islets to secrete insulin in response to a physiological glucose challenge.

Butyrate and acetate are products of GABA degradation. In our taxonomic analyses, the bacterial species most correlated with the abundance of PWY-5022 were *Eubacterium rectale* and *Roseburia intestinalis* (Spearman $\rho = 0.52$ and 0.30 , respectively, Figure 2c), both well-known butyrate-producing bacteria^{36,37}. Plasma butyrate levels were not measured in our study; current assays are challenging to perform and provide unreliable estimates³⁸. Whilst we consider the abundance of the PWY-5022 pathway to act as a proxy for butyrate production in the gut, we were unable to directly link PWY-5022 abundance to the amount of butyrate absorbed by the host. The abundance of PWY-5022 was poorly correlated with fecal butyrate levels (Spearman $\rho = 0.1$), and we did not detect any causal relationships between this SCFA and the 17 traits ($P > 0.05$), indicating that fecal butyrate is a poor proxy for butyrate production and absorption.

These results point towards a causal role for gut-produced butyrate that is focused on the dynamic insulin response to food ingestion, rather than the homeostatic mechanisms involved in the maintenance of glucose metabolism in the fasted state. Independent clinical

studies support this hypothesis. For example, an intervention study evaluating the role of *Bifidobacteria*-increasing prebiotics (fructo-oligosaccharides) in 35 healthy individuals showed that prebiotics decrease levels of butyrate-producing bacteria and result in adverse effect on glucose metabolism following an oGTT³⁹.

The PWY-5022 finding led us to consider the role of other SCFAs in metabolic and anthropometric traits. In our cross-sectional analysis within LL-DEEP, we had detected associations between fecal propionate levels and BMI (FDR < 0.1). Propionate is produced by different bacteria than those producing butyrate⁴⁰, and its three genetic predictors (variance explained = 6.3%, F-statistic = 21) were independent of those implicated in PWY-5022 abundance (Supplementary Table 4, 8). In MR analyses for the 17 traits of interest, we found that each SD increase in fecal propionate levels was causally associated with a 0.03 SD increase in BMI ($P = 0.0068$) and an odd's ratio (OR) = 1.15 for T2D ($P = 0.004$) (Supplementary Table 9), although these did not pass our significance threshold. No associations were evident in the reverse MR analysis testing the effect of T2D and BMI on fecal propionate levels ($P > 0.1$, Supplementary Table 10).

Of the two observed effects of fecal propionate, on BMI and T2D, the latter was more robust. The causal relationship on increased T2D risk was robust when other MR tests were performed ($P_{MR-PRESSO} = 0.03$, $P_{Weighted-Median} = 0.03$) and there was no evidence for pleiotropy ($P_{MR-PRESSOglobal} = 0.75$, $P_{RückerQ'(modified)} = 0.50$) (Supplementary Figure 5). By contrast, the effect of propionate on increased BMI was not significant when using other MR tests and there was also evidence for pleiotropy ($P_{MR-PRESSOglobal} = 2.0 \times 10^{-3}$, $P_{RückerQ'(modified)} = 9.2 \times 10^{-4}$) (Supplementary Table 9, Supplementary Figure 6). The pleiotropy in the BMI effect could be accounted for by SNP rs7142308 (NC_000014.8:g.79482379A>G) ($P_{MR-PRESSOOutlierTest} = 0.01$), located within a BMI-associated locus²⁰ but independent of the lead variant (rs7141420 (NC_000014.8:g.79899454C>T), $r^2 = 0.01$ with rs7142308 in 1000 Genomes Europeans).

Applying MR analyses to UK Biobank summary statistics, we replicated the relationship between fecal propionate levels and increased risk of T2D ($P_{IVW} = 0.01$, $P_{MR-PRESSO} = 0.007$, $P_{Weighted-Median} = 0.04$; $P_{IVWcombined} = 4 \times 10^{-5}$, Figure 3), and there was no evidence of pleiotropy ($P_{MR-PRESSOglobal} = 0.97$, $P_{RückerQ'(modified)} = 0.99$). The relationship between fecal propionate and BMI was again not robust to pleiotropy, highlighting the need for caution in interpreting this effect as causal (Supplementary Table 11).

Over 95% of gut-produced SCFAs are absorbed by the host⁴¹, such that increases in fecal propionate levels could be the consequence of either increased production or reduced absorption. The latter (which would link increased fecal propionate to reduced circulating levels) would be more consistent with the preponderance of evidence that indicates that SCFAs have a largely beneficial effect on energy balance and metabolic homeostasis^{4,10,12-14}. As with plasma butyrate, plasma propionate levels were not measured in our cohorts. Further studies are warranted to explore the mechanisms underlying this relationship between fecal propionate levels and T2D.

In summary, these data are consistent with a causal role for gut-produced SCFAs, specifically butyrate and propionate, with respect to energy balance and glucose homeostasis in man. We have shown that a genetically-influenced shift in the gut microbiome towards increased production of butyrate has beneficial effects on beta-cell function, though no impact on T2D risk could be detected. We have also demonstrated that host genetic variation that results in increased fecal propionate levels (reflecting some combination of increased production or impaired absorption) has impact on T2D-risk.

Although the LL-DEEP cohort represents the largest population study on the genetics of microbiome^{2,17,18}, it is still underpowered to capture the limited genetic component that has been estimated for microbiome features¹⁹. The results from this and other microbiome GWAS^{2,17,18} showed only limited direct overlap, highlighting the need for standardized protocols for data analyses and larger sample size⁴². This will be crucial also in the context of MR analyses, as expanded GWAS will deliver more robust genetic predictors⁴³. A better understanding of the complex interplay between gut microbiome and host metabolism will require expansion of current analyses and the ability to fold in measures of circulating SCFAs. Nevertheless, this study demonstrates that microbiome GWAS provide a route to causal inference that can guide and complement more direct experimental approaches, such as those based around fecal transplantation and animal models. We envisage that with expanded microbiome-genetic studies, for example the MiBioGen consortium⁴⁴, MR will become a standard tool for systematically screening a large number of hypotheses generated in current and future microbiome-wide association studies.

Online Methods

Study samples

The discovery cohort of this study is LifeLines-DEEP (LL-DEEP), a population-based cohort of 1,539 individuals from Northern Netherlands (age range 18–84 years) that is a subset of the largest Lifelines biobank (N = 167,000). For all LL-DEEP volunteers, an extensive dataset of measured and self-reported phenotypic information has been collected, as well as blood and stool specimens, all as described previously^{45,46}. Measurement of SCFAs in stool was carried out by gas chromatography-mass spectrometry following the method of García-Villalba et al⁴⁷.

To identify the appropriate threshold for the selection of genetic predictors of microbiome features we used the 500 Functional Genomics (500FG) cohort²⁸, an independent cohort of 534 healthy individuals from the Netherlands (age-range 18–75 years). Protocols for stool collection and metagenomic sequencing were similar to those used in LL-DEEP, as previously described⁴⁸.

All participants from both studies signed an informed consent form. The LL-DEEP study was approved by the institutional ethics review boards of the UMCG ([ClinicalTrials.gov](https://www.clinicaltrials.gov/ct2/show/study/NCT00775060) NCT00775060). The 500FG study was approved by the Ethical Committee of Radboud University Nijmegen (NL42561.091.12, 2012/550).

To replicate our findings we used genotype and phenotype data from the UK Biobank, a study of 500,000 subjects from the United Kingdom aged 45–65 years of age³⁵. Each participant provided a blood sample for DNA extraction and completed a detailed questionnaire providing baseline data. Individuals are also linked to electronic medical records on a number of traits including BMI and T2D.

Data generation and pre-processing

Genotyping—Genotype data was available for 1,268 LL-DEEP volunteers, as previously described^{2,45}. In brief, genotyping was carried out using two Illumina arrays, HumanCytoSNP-12 BeadChip and ImmunoChip. After standard per-sample and per-SNP quality control filters, data from the two arrays were merged and additional markers were imputed using the HRC reference panel v1.1⁴⁹ on the Michigan server (see URLs). For our analyses, we focused on 15,001,957 variants with imputation accuracy $RSQR > 0.3$. In the 500FG cohort, 516 samples were genotyped using the Illumina Human OmniExpress Exome-8 v1.0 SNP chip and, after standard quality controls checks²⁸, were imputed using the same procedure and reference panel used with LL-DEEP. The UK Biobank samples were genotyped using the Affymetrix UK BiLEVE Axiom array on an initial 50,000 participants. The remaining 450,000 participants were genotyped using the Affymetrix UK Biobank Axiom® array³⁵. Quality control on samples and genotypes were performed centrally and subsequent imputation was performed using the HRC reference panel at the Wellcome Centre Human Genetics.

Metagenomic sequencing—Metagenomic sequencing of the gut microbiome was performed using the Illumina HiSeq platform on 1,179 LL-DEEP samples. After applying per-sample and per-read quality filters², the profile of microbial composition was determined using Bracken pipeline (see URLs). In total, 903 taxonomies were identified and normalized using a log transformation; normalized non-zero values were then adjusted for age, sex and read depth using linear regression.

Functional profiling was performed using HUMAnN2 (v 0.4.0), which maps reads to a customized database of functionally annotated pan-genomes⁵⁰. This analysis identified 742 pathways from the MetaCyc metabolic pathway database⁵¹. Similar to the taxonomy data, we normalized pathway abundances using log transformation and corrected the normalized nonzero values for age, sex and read depth. We considered only non-zero values for analyses, and therefore restricted analyses to microbiome features (taxonomies and pathways) that had non-zero values in less than 50% of the samples and retained only one of pairs of pathways or bacteria showing > 0.99 Spearman correlation. This filtering resulted in a final set of 796 features (273 taxa and 523 pathways) that were used for analyses.

We further confined all statistical analyses to normo-glycemic samples with good quality genetic and microbiome data. Normo-glycemic status was assigned to samples from individuals not reported to have diabetes or to be taking oral anti-diabetes medications and who had fasting glucose levels < 7 mmol/L. We also removed individuals who were taking antibiotics at the time of the stool collection. This filtering resulted in a final set of 952

samples available for analyses. In the 500FG cohort, we used the same filters and selected 445 normo-glycemic samples with both genetic and microbiome data for analyses.

Genome-wide association scans of anthropometric and glycemic traits—We downloaded full GWAS summary statistics from 9 studies that represented 17 GWAS for different anthropometric and glycemic traits. These traits were BMI and waist-hip-ratio (WHR), fasting glucose, insulin and pro-insulin, 2hr glucose, HOMA-derived measurements of insulin resistance (HOMA-IR) and sensitivity (HOMA-B)), glycosylated hemoglobin (HbA_{1c}), T2D, and 7 insulin response parameters measured during an oral glucose tolerance test (oGTT) (Supplementary Table 1 and URLs). SNP names and genomic positions were aligned to the genomic build GRCh37/hg19.

Statistical Analysis

Correlation of short chain fatty acids and microbiome features with anthropometric and glycemic traits—We correlated 5 short chain fatty acids (Acetate, Butyrate, Propionate, Calproate and Valerate) and 796 other microbiome features (taxa or pathways) with measured anthropometric (BMI and WHR) and glycemic traits (fasting glucose, insulin, HbA_{1c}, HOMA-IR and HOMA-B) in the LL-DEEP cohort.

Anthropometric and glycemic traits were adjusted for age, sex, and BMI (except for BMI phenotype). We used the non-parametric Spearman correlation test (*cor.test(method="Spearman")* function in R (v3.3)) and considered results significant when the multiple-testing-adjusted two-sided *P*-value was < 0.1. The multiple-testing-adjusted *P*-value, FDR *P*, was calculated using the Benjamini-Hochberg procedure in the *p.adjust()* function in R (v3.3) (see URLs).

Genome-wide association analyses of short-chain fatty acids and microbiome features—For each microbiome feature and short-chain fatty acid, we performed a genome-wide association scan in LL-DEEP samples by re-processing data from our previous study in a different manner². In particular: a) we re-mapped metagenomic reads to a more recent database, b) we restricted analyses to only normo-glycemic samples and those who were not under antibiotics, and c) we performed genetic analyses using a linear mixed model that accounts for population structure instead of the Spearman correlation method. In particular for genetic analyses, we used EPACTS (v3.2.6)⁵², a software program that performs a linear mixed model adjusted with a genomic-based kinship matrix that is calculated using all quality-checked genotyped autosomal SNPs with minor allele frequency > 1%. The advantage of this model is that the kinship matrix encodes a wide range of sample structures, including both cryptic relatedness and population stratification; this produces more robust results than standard linear regression. All traits were inverse quantile normalized before genetic analysis. Specifically for SFCAs, age, sex, Chromogranin A, stool type according to Bristol scale, and BMI were added as covariates.

The variance explained (adjusted R squared) and the F-statistic for each microbiome feature were extracted from a linear model that fitted all the selected genetic predictors on the normalized, covariates-adjusted microbiome feature.

Mendelian Randomization analyses with 17 GWAS traits—The Mendelian Randomization procedure consists of two steps: i) identification of proper instrumental variables or genetic predictors, e.g. variants independently associated with the exposure factor, and ii) calculation of causal estimates. For each GWAS summary statistic, we first selected independent SNPs using the clumping procedure in *PLINK* v1.9 (see URLs) and setting a linkage disequilibrium threshold of $r^2 < 0.1$ in a 500-Kb window. Linkage disequilibrium was calculated using the LL-DEEP cohort when running the clumping procedure on the GWAS of microbiome features and short chain fatty acids, whereas for GWAS of anthropometric and glycaemic traits we used the linkage disequilibrium estimates from the 1000 Genomes phase 3 European samples.

Furthermore, since the majority of the downloaded GWAS were based on the HapMap2 genetic map, for each independently associated variant, we identified the best HapMap2 proxy ($r^2 > 0.8$) or discarded that variant if no proxy was available.

Finally, we selected only variants that showed association at $P < 1 \times 10^{-5}$. We identified this as the optimal P -value threshold to use for selection of genetic predictors associated with microbiome features because this threshold led to a larger variance explained, on average, of the same microbiome features in the 500FG cohort (Supplementary Figure 1). For consistency, we used the same threshold and procedure for selecting genetic predictors from the downloaded GWAS on anthropometric and glycaemic traits.

To calculate causal estimates, we used the inverse-variance weighted (IVW) method³² as a two-sample MR analysis of summary association statistics of the exposure and the outcome. Specifically, we estimated the causal effect in a fixed-effect meta-analysis framework, i.e. as a sum of single-SNP causal effects (derived as a ratio of the SNP-effect on the outcome by the SNP-effect on the exposure) weighted by the inverse of their variance (derived as a squared ratio of the SNP-standard deviation on the outcome on SNP-effect on the exposure). The P -value was calculated as $P = 2 * (1 - \Phi(Z))$, where $\Phi(Z)$ is the standard normal cumulative distribution function and Z is ratio of the combined (using inverse variance weights) causal effect and its standard error. Of note, the causal estimate is equivalent to that obtained as a weighted linear regression of the outcome SNP-effects on the exposure SNP-effects with a fixed intercept of 0 and with the inverse of the variance of the effect sizes on the outcome as weights. For analyses, we set the effect allele of the genetic predictors to be the allele with the positive direction. We also calculated causal estimates using additional MR methods: MR-PRESSO³⁰, which removes pleiotropy by identifying and discarding influential outlier predictors from the IVW test and uses a t-test to calculate P -values; the weighted-median test³¹, which uses a statistical estimator that is robust to the presence of pleiotropy in a subset ($< 50\%$) of the predictors; and the MR-Egger³², which adjusts for average horizontal pleiotropy and assumes that $> 50\%$ of the predictors have pleiotropy. Furthermore, we specifically evaluated presence of pleiotropy using MR-PRESSO Global test³⁰ and the modified Rücker's Q' test³³.

Calculation of significance threshold—To define our significance threshold for the IVW-based MR analyses, we first run a principal component analysis of the 245 microbiome features, and observed that the total variability could be explained by the first 57 principal

component axes. To derive the number of independent anthropometric and metabolic traits out of the 17 of interest, we used pairwise genetic correlation calculated using LDscore regression (LDscore v1.0.0). Variants were restricted to those from HapMap3 and pre-computed LD Scores estimated in subjects of European descent were used as recommended by the authors⁵³. Traits were hierarchically clustered based on genetic correlation values ρ_g , with dissimilarity metric $(1-\rho_g)/2$ (Supplementary Figure 2). The number of resulting clusters was used to define the number of independent traits. Genetic correlation could not be calculated with four insulin secretion traits so we counted these as fully independent traits. We set our multiple testing significance threshold at 1.3×10^{-4} ($0.05/(57*7)$).

Mendelian randomization analyses in UK Biobank—We first calculated association of the 12 genetic predictors (9 for PWY-5022 and 3 for fecal propionate) with 7 metabolic and anthropometric traits (BMI, body Fat %, WHR, visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), obesity and T2D) using a linear mixed model as implemented in BOLT-LMM (v2.3.2)⁵⁴. T2D status was defined according to the definition used by Eastwood et al.⁵⁵; BMI was defined according to that used by the GIANT consortium²⁰ and obesity was defined by ICD code 278. Analyses were restricted to 442,817 unrelated individuals of European descent and were adjusted for age, sex, genotyping array and 6 genetic principal components; WHR was also adjusted for BMI. We then used the summary statistics at these 12 variants to estimate causal relationships and investigate presence of pleiotropy by applying the same statistical tests that were used with the GWAS summary statistics and described in the previous paragraph.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank the participants and staff of the LL-DEEP cohort for their collaboration, the UMCG Genomics Coordination center, the UG Center for Information Technology and their sponsors BBMRI-NL & TarGet for storage and compute infrastructure. We are also grateful to Marc Jan Bonder for help in formatting summary statistics, to Rinse K. Weersma and Yang Li for discussions and to Kate Mc Intyre for editing the manuscript. Part of this work was conducted using the UK Biobank resource under application number 9161.

This project was funded by: IN-CONTROL CVON grant CVON2012-03 to M.G.N., A.Z., L.J. and J.F.; Top Institute Food and Nutrition (TiFN, Wageningen, the Netherlands) grant TiFN GH001 to C.W.; the Netherlands Organization for Scientific Research (NWO) grants NWO-VENI 016.176.006 to M.O., NWO-VIDI 864.13.013 to J.F., and NWO-VIDI 016.Vidi.178.056 to A.Z.; NWO Spinoza Prizes SPI 92-266 to C.W. and SPI 94-212 to M.G.N.; the European Research Council (ERC)-Starting grant ERC #715772 to A.Z.; the FP7/2007-2013/ERC Advanced Grant (agreement 2012-322698) to C.W.; the ERC Consolidator Grant ERC#310372 to M.G.N.; Tripartite Immunometabolism consortium (TrIC) – Novo Nordisk Foundation Grant#NNF15CC0018486 to M.M.; and Wellcome grants 090532, 098381, 106130, and 203141 to M.M.. A.Z. also holds a Rosalind Franklin Fellowship from the University of Groningen. M.M. is a Wellcome Senior Investigator, and a National Institute of Health Research Senior Investigator. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.

References

1. Zhernakova A et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. *Science* 352, 565–9 (2016). [PubMed: 27126040]

2. Bonder MJ et al. The effect of host genetics on the gut microbiome. *Nat Genet* 48, 1407–1412 (2016). [PubMed: 27694959]
3. Evans DM & Davey Smith G Mendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality. *Annu Rev Genomics Hum Genet* 16, 327–50 (2015). [PubMed: 25939054]
4. Larsen N et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. *PLoS One* 5, e9085(2010). [PubMed: 20140211]
5. Karlsson FH et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. *Nature* 498, 99–103 (2013). [PubMed: 23719380]
6. Ley RE et al. Obesity alters gut microbial ecology. *Proc Natl Acad Sci U S A* 102, 11070–5 (2005). [PubMed: 16033867]
7. Kreznar JH et al. Host Genotype and Gut Microbiome Modulate Insulin Secretion and Diet-Induced Metabolic Phenotypes. *Cell Rep* 18, 1739–1750 (2017). [PubMed: 28199845]
8. Brunkwall L & Orho-Melander M The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities. *Diabetologia* 60, 943–951 (2017). [PubMed: 28434033]
9. Kootte RS et al. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. *Cell Metab* 26, 611–619 e6 (2017). [PubMed: 28978426]
10. Zhang X et al. Human gut microbiota changes reveal the progression of glucose intolerance. *PLoS One* 8, e71108(2013). [PubMed: 24013136]
11. Rios-Covian D et al. Intestinal Short Chain Fatty Acids and their Link with Diet and Human Health. *Front Microbiol* 7, 185(2016). [PubMed: 26925050]
12. Pingitore A et al. The diet-derived short chain fatty acid propionate improves beta-cell function in humans and stimulates insulin secretion from human islets in vitro. *Diabetes Obes Metab* 19, 257–265 (2017). [PubMed: 27761989]
13. Chambers ES et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. *Gut* 64, 1744–54 (2015). [PubMed: 25500202]
14. Zhao L et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. *Science* 359, 1151–1156 (2018). [PubMed: 29590046]
15. Peng L, He Z, Chen W, Holzman IR & Lin J Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. *Pediatr Res* 61, 37–41 (2007). [PubMed: 17211138]
16. Schwartz A et al. Microbiota and SCFA in lean and overweight healthy subjects. *Obesity (Silver Spring)* 18, 190–5 (2010). [PubMed: 19498350]
17. Turpin W et al. Association of host genome with intestinal microbial composition in a large healthy cohort. *Nat Genet* 48, 1413–1417 (2016). [PubMed: 27694960]
18. Goodrich JK et al. Genetic Determinants of the Gut Microbiome in UK Twins. *Cell Host Microbe* 19, 731–43 (2016). [PubMed: 27173935]
19. Rothschild D et al. Environment dominates over host genetics in shaping human gut microbiota. *Nature* 555, 210–215 (2018). [PubMed: 29489753]
20. Locke AE et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature* 518, 197–206 (2015). [PubMed: 25673413]
21. Shungin D et al. New genetic loci link adipose and insulin biology to body fat distribution. *Nature* 518, 187–196 (2015). [PubMed: 25673412]
22. Manning AK et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. *Nat Genet* 44, 659–69 (2012). [PubMed: 22581228]
23. Strawbridge RJ et al. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. *Diabetes* 60, 2624–34 (2011). [PubMed: 21873549]

24. Soranzo N et al. Common variants at 10 genomic loci influence hemoglobin A(1)(C) levels via glyceic and nonglyceic pathways. *Diabetes* 59, 3229–39 (2010). [PubMed: 20858683]
25. Prokopenko I et al. A central role for GRB10 in regulation of islet function in man. *PLoS Genet* 10, e1004235(2014). [PubMed: 24699409]
26. Saxena R et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. *Nat Genet* 42, 142–8 (2010). [PubMed: 20081857]
27. Scott RA et al. An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. *Diabetes* 66, 2888–2902 (2017). [PubMed: 28566273]
28. Li Y et al. A Functional Genomics Approach to Understand Variation in Cytokine Production in Humans. *Cell* 167, 1099–1110 e14 (2016). [PubMed: 27814507]
29. Burgess S, Butterworth A & Thompson SG Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol* 37, 658–65 (2013). [PubMed: 24114802]
30. Verbanck M, Chen CY, Neale B & Do R Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet* 50, 693–698 (2018). [PubMed: 29686387]
31. Bowden J, Davey Smith G, Haycock PC & Burgess S Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol* 40, 304–14 (2016). [PubMed: 27061298]
32. Bowden J, Davey Smith G & Burgess S Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol* 44, 512–25 (2015). [PubMed: 26050253]
33. Bowden J et al. Improving the accuracy of two-sample summary data Mendelian randomization: moving beyond the NOME assumption. Preprint at <https://www.biorxiv.org/content/early/2018/10/11/159442> (2018).
34. Rucker G, Schwarzer G, Carpenter JR, Binder H & Schumacher M Treatment-effect estimates adjusted for small-study effects via a limit meta-analysis. *Biostatistics* 12, 122–42 (2011). [PubMed: 20656692]
35. Bycroft C et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* 562, 203–209 (2018). [PubMed: 30305743]
36. Duncan SH, Hold GL, Barcenilla A, Stewart CS & Flint HJ *Roseburia intestinalis* sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. *Int J Syst Evol Microbiol* 52, 1615–20 (2002). [PubMed: 12361264]
37. Pryde SE, Duncan SH, Hold GL, Stewart CS & Flint HJ The microbiology of butyrate formation in the human colon. *FEMS Microbiol Lett* 217, 133–9 (2002). [PubMed: 12480096]
38. Jakobsdottir G, Bjerregaard JH, Skovbjerg H & Nyman M Fasting serum concentration of short-chain fatty acids in subjects with microscopic colitis and celiac disease: no difference compared with controls, but between genders. *Scand J Gastroenterol* 48, 696–701 (2013). [PubMed: 23600961]
39. Liu F et al. Fructooligosaccharide (FOS) and Galactooligosaccharide (GOS) Increase Bifidobacterium but Reduce Butyrate Producing Bacteria with Adverse Glycemic Metabolism in healthy young population. *Sci Rep* 7, 11789(2017). [PubMed: 28924143]
40. Louis P & Flint HJ Formation of propionate and butyrate by the human colonic microbiota. *Environ Microbiol* 19, 29–41 (2017). [PubMed: 27928878]
41. den Besten G et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. *J Lipid Res* 54, 2325–40 (2013). [PubMed: 23821742]
42. Kurilshikov A, Wijmenga C, Fu J & Zhernakova A Host Genetics and Gut Microbiome: Challenges and Perspectives. *Trends Immunol* 38, 633–647 (2017). [PubMed: 28669638]
43. Taylor AE et al. Mendelian randomization in health research: using appropriate genetic variants and avoiding biased estimates. *Econ Hum Biol* 13, 99–106 (2014). [PubMed: 24388127]
44. Wang J et al. Meta-analysis of human genome-microbiome association studies: the MiBioGen consortium initiative. *Microbiome* 6, 101(2018). [PubMed: 29880062]

Methods-Only References

45. Tigchelaar EF et al. Cohort profile: LifeLines DEEP, a prospective, general population cohort study in the northern Netherlands: study design and baseline characteristics. *BMJ Open* 5, e006772(2015).
46. Li N et al. Pleiotropic effects of lipid genes on plasma glucose, HbA1c, and HOMA-IR levels. *Diabetes* 63, 3149–58 (2014). [PubMed: 24722249]
47. Garcia-Villalba R et al. Alternative method for gas chromatography-mass spectrometry analysis of short-chain fatty acids in faecal samples. *J Sep Sci* 35, 1906–13 (2012). [PubMed: 22865755]
48. Schirmer M et al. Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity. *Cell* 167, 1125–1136 e8 (2016). [PubMed: 27814509]
49. McCarthy S et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet* 48, 1279–83 (2016). [PubMed: 27548312]
50. Franzosa EA et al. Species-level functional profiling of metagenomes and metatranscriptomes. *Nat Methods* 15, 962–968 (2018). [PubMed: 30377376]
51. Vatanen T et al. Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. *Cell* 165, 842–53 (2016). [PubMed: 27133167]
52. Kang HM et al. Variance component model to account for sample structure in genome-wide association studies. *Nat Genet* 42, 348–54 (2010). [PubMed: 20208533]
53. Bulik-Sullivan BK et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* 47, 291–5 (2015). [PubMed: 25642630]
54. Loh PR et al. Efficient Bayesian mixed-model analysis increases association power in large cohorts. *Nat Genet* 47, 284–90 (2015). [PubMed: 25642633]
55. Eastwood SV et al. Algorithms for the Capture and Adjudication of Prevalent and Incident Diabetes in UK Biobank. *PLoS One* 11, e0162388(2016). [PubMed: 27631769]




Figure 1. Schematic representation of the study

Figure 1 is a schematic representation of our study, highlighting for each step the research question we want to answer, the analysis workflow, and the data used. We first aimed to identify which microbiome feature (taxa, microbiome pathway or short-chain fatty acid (SCFA)) correlated with metabolic traits in the LifeLines-DEEP (LL-DEEP) cohort (Step 1). We then performed genome-wide association (GWA) analysis in LL-DEEP to identify genetic predictors of those microbiome features (Step 2), and used the genetic predictors to estimate causal relationships through bidirectional Mendelian Randomization analysis and

effect sizes for metabolic traits extracted from summary statistics of large GWA studies (Step 3). Finally, we validated our causality results using the UK Biobank (Step 4).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 2. Causal effect of butyrate-producing activity of the gut on glucose-stimulated insulin response

a) Schematic representation of the Mendelian Randomization analysis results: genetic predisposition to higher abundance of butyrate-producing microbiome pathway PWY-5022 (4-aminobutanoate degradation V pathway) is associated with insulin response after glucose challenge. The causal effect of PWY-5022 was also seen on other insulin response parameters, and the forest plot in panel **(b)** represents the magnitude of the effect on each parameter per one-standard-deviation increase in pathway abundance, as estimated in the inverse-variance weighted Mendelian Randomization (MR) analysis. MR analysis was carried out using up to nine genetic predictors and their effect size from LL-DEEP (952 samples) and MAGIC summary statistics (trait specific sample sizes are: $AUC_{\text{insulin}}/AUC_{\text{glucose}} = 4213$; insulin at 30 min = 4,409; $AUC_{\text{insulin}} = 4,324$; correct insulin response = 4,789; insulin increase at 30 min = 4,447; Disposition index = 5,130) (Methods, Supplementary Table 4 and 5). Corresponding two-sided *P*-values are given in the annexed

table. (e) Correlation plots with PWY-5022 abundance and the bacteria correlating the most with it in 950 LL-DEEP samples (subset of the 952 normo-glycemic samples for which presence of those bacteria was detected). The Spearman correlation coefficient ρ is given in blue in each panel.




Figure 3. Causal effect of fecal propionate on type 2 diabetes (T2D)

a) Schematic representation of the Mendelian Randomization analysis results: genetic predisposition to higher fecal propionate levels is associated with increased risk of T2D. **b)** A forest plot depicts the magnitude of the causal effect on T2D per each one-standard-deviation increase in fecal butyrate levels, as estimated by the inverse-variance weighted Mendelian Randomization (MR) analysis. MR analysis was carried out using the three genetic predictors derived in LifeLines-DEEP (LL-DEEP) and their effects in the discovery data set (DIAGRAM; 26,676 T2D cases and 132,532 controls) and in the replication cohort (UK Biobank; 19,119 T2D cases and 423,698 controls). The effect derived combining the two causal effects (from discovery and replication) with an inverse-variance weighted meta-analysis approach is also given. Corresponding two-sided *P*-values are listed in the annexed table. OR, odd's ratio.